重组人血管内皮抑制素联合TP方案在晚期EGFR野生型肺鳞状细胞癌患者的疗效观察

doi:10.3760/cma.j.issn.1673-422X.2017.10.006

摘要/Abstract

摘要： 目的探讨重组人血管内皮抑制素联合TP方案（紫杉醇+顺铂）治疗晚期表皮生长因子受体（EGFR）野生型肺鳞状细胞癌的疗效。方法选取2012年1月至2015年2月在重庆三峡中心医院就诊的肺鳞状细胞癌患者100例为研究对象，根据治疗方法分为单纯组（n=50）和联合组（n=50），单纯组使用TP方案，联合组在TP方案的基础上使用重组人血管内皮抑制素。依据实体瘤疗效评价标准1.1版（RECIST 1.1）进行治疗效果评价，并分析近期疗效、远期疗效、不良反应、住院时间及住院费用。结果联合组患者的客观有效率为52.0%（26/50），明显高于单纯组的16.0%（8/50），差异有统计学意义（χ2=14.429，P=0.007）。联合组患者的疾病控制率明显高于单纯组（80.0%∶52.0%），差异有统计学意义（χ2=8.734，P=0.009）。与单纯组患者相比，联合组患者的中位无进展生存期（8.4个月∶6.3个月）和总生存期（17.7个月∶11.5个月）明显延长，差异有统计学意义（χ2=5.390，P=0.025；χ2=3.993，P=0.035）。单纯组患者的各种不良反应发生率与联合组基本一致，差异无统计学意义（均P>0.05）。与单纯组相比，联合组患者住院时间明显延长［（23.5±2.8）周∶（18.2±3.5）周］，住院费用明显增加［（112 453.9±994.9）元∶（87 821.4±943.2）元］，差异有统计学意义（t=8.361，P＜0.001；t=127.051，P＜0.001），但联合组患者满意度显著高于单纯组患者（88.0%∶64.0%，χ2=4.210，P=0.017）。结论应用重组人血管内皮抑制素联合TP方案治疗晚期EGFR野生型肺鳞状细胞癌效果较好，不良反应发生率低，适于临床推广应用。

关键词: 肿瘤, 鳞状细胞, 肺肿瘤, 血管抑制素类, 顺铂, 紫杉醇

Abstract: ObjectiveTo evaluate the efficacy of recombinant human endostatin combined with TP (paclitaxel + cisplatin) in the treatment of advanced epidermal growth factor receptor (EGFR) squamous cell lung carcinoma. MethodsFrom January 2012 to February 2015, 100 patients with squamous cell lung carcinoma in Chongqing Three Gorges Central Hospital for medical treatment were selected as the subjects. According to different treatment methods, they were divided into single group (n=50) and combined group (n=50). The single group used the TP protocol and the combined group was treated with recombinant human endostatin on the basis of the TP protocol. The therapeutic effect was evaluated according to the Response Evaluation Criteria In Solid Tumors 1.1 (RECIST 1.1). The shortterm effects, longterm effects, adverse reactions, hospitalization time and expenses were also analyzed. ResultsThe objective effective rate in the combined group ［52.0% (26/50)］ was significantly higher than that in the single group ［16.0% (8/50)］, with a significant difference (χ2=14.429, P=0.007). The disease control rate in the combined group was higher than that in the single group (80.0% vs. 52.0%), with a significant difference (χ2=8.734, P=0.009). Compared with the patients in the single group, the median progression free survival (8.4 months vs. 6.3 months) and overall survival (17.7 months vs. 11.5 months) in the combined group were prolonged obviously, with significant differences (χ2=5.390, P=0.025; χ2=3.993, P=0.035). The incidence rates of adverse reactions in single group were basically the same compared with the combined group, and the difference was not statistically significant (all P>0.05). Compared with the single group, the hospitalization time in combined group was longer ［(23.5±2.8) weeks vs. (18.2±3.5) weeks］, and the expenses in combined group was higher ［(112 453.9±994.9) yuan vs. (87 821.4±943.2) yuan］, with significant differences (t=8.361, P＜0.001; t=127.051, P＜0.001). But the satisfaction of patients in combined group was significantly higher than that in single group (88.0% vs. 64.0%, χ2=4.210, P=0.017). ConclusionRecombinant human endostatin combined with TP regimen is effective in the treatment of advanced EGFR wildtype squamous cell lung carcinoma, and has a low incidence of adverse reactions. It is suitable for clinical application.

Key words: Neoplasms, squamous cell, Lung neoplasms, Angiostatins, Cisplatin, Paclitaxel

王伟,任必勇. 重组人血管内皮抑制素联合TP方案在晚期EGFR野生型肺鳞状细胞癌患者的疗效观察[J]. 国际肿瘤学杂志, 2017, 44(10): 745-748.

Wang Wei, Ren Biyong. Efficacy of recombinant human endostatin combined with TP regimen on patients with advanced EGFR wild type squamous cell lung carcinoma[J]. Journal of International Oncology, 2017, 44(10): 745-748.

参考文献

［1］吕远, 姜镕, 马春华, 等. 重组人血管内皮抑制素静脉持续泵入联合窗口期动脉灌注化疗治疗晚期肺鳞癌的临床观察［J］. 中国肺癌杂志, 2015, 18 (8): 500504. DOI: 10.3779/j.issn.10093419.2015.08.05. ［2］米热古丽·阿不都热合曼, 杜探·赛肯, 刘丹玉. 吉西他滨联合顺铂一线治疗对Ⅲb～Ⅳ期肺鳞癌的疗效评价［J］. 实用肿瘤杂志, 2015, 30(5): 459462. DOI: 10.13267/j.cnki.syzlzz.2015.05.016. ［3］吴占庆, 马强, 高玉风. 重组人血管内皮抑制素联合肝动脉化疗栓塞后肝癌患者血清VEGF、HIF1α、OPN、CTGF水平变化［J］. 中国生化药物杂志, 2015, 35(6): 98101. ［4］沈钰新, 赵伟新, 王升平, 等. 重组人血管内皮抑制素单药对非小细胞肺癌肿瘤血管微环境影响的初步研究［J］. 中国癌症杂志. 2015, 25(10): 817822. DOI: 10.3969/j.issn.10073969.2015.10.011. ［5］ Bao D, Jin X, Ma Y, et al. Comparison of the structure and biological activities of wildtype and mutant livertargeting peptide modified recombinant human endostatin (rESCSP) in human hepatocellular carcinoma HepG2 cells［J］. Protein Pept Lett, 2015, 22(5): 470479. ［6］ Bao Y, Peng F, Zhou QC, et al. Phase Ⅱ trial of recombinant human endostatin in combination with concurrent chemoradiotherapy in patients with stage Ⅲ nonsmallcell lung cancer［J］. Radiother Oncol, 2015, 114(2): 161166. DOI: 10.1016/j.radonc.2014.11.039. ［7］邢镨元, 郝学志, 胡兴胜, 等. 重组人血管内皮抑制素在晚期肺鳞癌治疗中的临床应用［J］. 中国肺癌杂志, 2016, 19(10): 670674. DOI: 10.3779/j.issn.10093419.2016.10.06. ［8］ Teng C, Li LI, Shen W, et al. Pleural synovial sarcoma patient treated with combined chemotherapy and Endostar, plus sunitinib maintenance therapy: a case report and review of the literature［J］. Oncol Lett, 2015, 10(2): 11411144. DOI: 10.3892/ol.2015.3311. ［9］陈青青, 王华庆, 张会来, 等. 恩度联合CHOPT方案治疗AITL的初步疗效观察［J］. 实用肿瘤杂志, 2015, 30(1): 6064. DOI: 10.13267/j.cnki.syzlzz.2015.01.016. ［10］尹竺晟, 戈伟, 罗卫. 肿瘤标志物在非小细胞肺癌患者诊断中的价值［J］. 中国医药导报, 2016, 13(23): 102105. ［11］杨剑, 卢伟, 蒋富强, 等. 重组人血管内皮抑制素联合血管介入治疗难治性晚期肺癌的临床研究［J］. 现代仪器与医疗, 2015, 21(3): 2729. DOI: 10.11876/mimt201503010. ［12］ Hirai F, Seto T, Inamasu E, et al. Feasibility of cisplatin/pemetrexed with 15 mg/kg bevacizumab for the treatment of patients with advanced nonsquamous nonsmall cell lung cancer［J］. Oncol Lett, 2015, 9(6): 25772582. DOI: 10.3892/ol.2015.3086. ［13］付蕾, 樊青霞, 王留兴, 等. 重组人血管内皮抑制素联合含铂方案治疗晚期非小细胞肺癌的临床观察［J］. 肿瘤, 2012, 32(1): 6064. DOI: 10.3781/j.issn.10007431.2012.01.011. ［14］张媛媛. 重组人血管内皮抑制素(恩度)联合化疗(GP方案)一线治疗晚期肺鳞癌的临床研究［D］. 杭州: 浙江大学, 2014. ［15］ Lin K, Ye P, Liu J, et al. Endostar inhibits hypoxiainduced cell proliferation and migration via the hypoxiainducible factor1 alpha/vascular endothelial growth factor pathway in vitro［J］. Mol Med Rep, 2015, 11(5): 37803785. DOI: 10.3892/mmr.2014.3131. ［16］戴文鑫, 吴智勇, 陈娟, 等. 重组人血管内皮抑制素在晚期非小细胞肺癌治疗中的效果观察［J］. 检验医学与临床, 2015, 12(10): 14521453. DOI: 10.3969/j.issn.16729455.2015.10.052. ［17］ Kim JS, Kim ES, Liu D, et al. Prognostic implications of tumoral expression of insulin like growth factors 1 and 2 in patients with nonsmallcell lung cancer［J］. Clin Lung Cancer, 2014, 15(3): 213221. DOI: 10.1016/j.cllc.2013.12.006. ［18］时昌立, 秦德华, 丁广成, 等. miR517a3p对人肺鳞癌细胞生长和转移的影响及分子机制［J］. 中国老年学杂志, 2017, 37(9): 21322134. DOI: 10.3969/j.issn.10059202.2017.09.021.

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲. 血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	袁健, 黄燕华. Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[4]	陈红健, 张素青. 血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[5]	郭泽浩, 张俊旺. PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[6]	张百红, 岳红云. 新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[7]	许凤琳, 吴刚. EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[8]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[9]	张蕊, 褚衍六. 基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[10]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[11]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东. ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[12]	刘静, 刘芹, 黄梅. 基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[13]	杨琳, 路宁, 温华, 张明鑫, 朱琳. 炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[14]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝. 癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[15]	张宁宁, 杨哲, 檀丽梅, 李振宁, 王迪, 魏永志. 宫颈细胞DNA倍体分析联合B7-H4和PKCδ对宫颈癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(5): 286-291.